Alcohol Use Disorder (AUD)NCT07036055
Research on the Heart-Brain Coupling Mechanisms and Interventions for Emotional Inhibitory Control Deficits in Individuals With Alcohol Use Disorder
A study testing Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training in people with Alcohol Use Disorder (AUD), run by Shanghai Mental Health Center at 1 site in China.
Trial summary
The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). Read more about this study
- Who is it for?
- Ages 18 to 55 years, men only
- Conditions the study is for
- Alcohol Use Disorder (AUD)
- What is being tested?
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 15 Mar 2024to 31 Aug 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (AUD).
- Aged 18-55 years.
- Currently in the post-acute withdrawal phase (≥2 weeks since last alcohol use).
- No severe psychiatric comorbidities (e.g., schizophrenia, bipolar disorder).
- No neurological disorders (e.g., epilepsy, traumatic brain injury).
- Willing to provide informed consent.
Who cannot join
- Dependence on other substances (except nicotine).
- Severe physical illness requiring immediate treatment.
- Active infectious diseases (e.g., HIV, hepatitis).
- Inability to complete study procedures (e.g., cognitive impairment).
- (For healthy controls in Study 1, inclusion required AUDIT score ≤8, no psychiatric/neurological history, and matched demographics.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Targeting Brain-Heart Coupling to Improve Emotional Inhibitory Control in Alcohol Use Disorder: Mechanistic Insights and Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Mindfulness Training
The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). The study also aims to explore the brain-heart coupling mechanisms underlying these control deficits.
The main questions it aims to answer are:
Read more
Do individuals with AUD have abnormal brain-heart coupling associated with impaired emotional inhibitory control? Can taVNS combined with mindfulness training enhance emotional inhibitory control in individuals with AUD compared to sham stimulation? Researchers will compare a group receiving taVNS plus mindfulness training to a group receiving sham stimulation plus mindfulness training to see whether the active intervention improves behavioral performance and brain-heart coupling.
Participants will:
Complete an emotional Go/NoGo task while EEG and ECG data are recorded Receive 10 days of either real or sham taVNS combined with mindfulness training Complete questionnaires and cognitive assessments before and after the intervention
Read the detailed description
This two-part clinical study investigates the mechanisms and intervention effects related to emotional inhibitory control deficits in individuals with Alcohol Use Disorder (AUD), with a specific focus on brain-heart coupling (also referred to as brain-heart interplay, BHI). The study aims to identify the neurophysiological characteristics underlying inhibitory control impairments in AUD and evaluate whether non-invasive vagus nerve stimulation combined with mindfulness training can enhance emotional regulation and cognitive function.
Study 1: Mechanism Exploration Study 1 adopts a case-control observational design. A total of 28 individuals diagnosed with AUD (based on DSM-5 criteria) and 28 age- and education-matched healthy controls are recruited. Participants complete an emotional Go/NoGo task under EEG-ECG hyperscanning. Emotional inhibitory control performance is assessed through behavioral indices (reaction time, error rate) and further analyzed using the Hierarchical Drift Diffusion Model (HDDM) to quantify latent cognitive processing parameters (e.g., drift rate, boundary separation, non-decision time). Brain-heart coupling is evaluated through resting-state EEG-ECG data using multiscale coupling coefficients and maximal information coefficient (MIC) between heart rate variability (HRV) and cortical oscillations (particularly α, β, and θ bands).
Primary outcomes include:
Drift rate and inhibitory control accuracy under emotional interference Degree of BHI (HRV-EEG coupling strength and directionality) The moderating effect of self-reported emotion regulation ability (measured via DERS)
Study 2: Intervention Evaluation
Study 2 is a single-blind randomized controlled trial (RCT) involving 60 AUD participants randomly assigned to:
Active group (n=30): taVNS combined with mindfulness training Control group (n=30): sham stimulation combined with mindfulness training Participants in both groups receive daily 30-minute sessions for 10 consecutive days. taVNS is delivered using a wearable ear-clip device targeting the auricular branch of the vagus nerve (cymba conchae), with stimulation parameters set at 25 Hz, pulse width of 200 μs, and intensity adjusted to individual sensory threshold. Mindfulness training is conducted by a trained therapist, focusing on breath awareness and body scanning.
Outcome measures are collected pre- and post-intervention and include:
Emotional inhibitory control performance under the Go/NoGo paradigm HDDM-derived cognitive parameters (e.g., drift rate) EEG-ECG-based BHI metrics (HRV-EEG coupling during rest) Self-reported anxiety (GAD-7), depressive symptoms (PHQ-9), and alcohol craving Adverse events monitoring and adherence logs Data Acquisition and Processing EEG signals are recorded using a 64-channel portable system (10-20 system); ECG is simultaneously recorded.
Signals are preprocessed in EEGLAB (bandpass filtering, artifact correction via ASR), with HRV features extracted via Kubios.
HDDM modeling is conducted in Python (Bayesian MCMC estimation), and BHI is analyzed through mutual information, MIC, and transfer entropy metrics.
Sample Size and Statistical Plan Sample size was estimated based on prior effect sizes observed in similar taVNS and mindfulness interventions. Power analysis indicated 28 subjects per group achieves >80% power to detect moderate group × time interaction effects.
Statistical analyses include:
Mixed-effects ANOVA for behavioral and neural outcomes Regression models to assess mediation and moderation effects (e.g., emotion regulation ability) Pearson/Spearman correlation between physiological and behavioral measures All analyses follow intention-to-treat principles with imputation for missing data where appropriate (e.g., multiple imputation for <10% missing).
- Conditions
- Alcohol Use Disorder (AUD)
- Being tested
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Stimulation, Mindfulness Training
- Keywords
- Alcohol Use Disorder (AUD), transcutaneous auricular vagus nerve stimulation (taVNS), brain-heart coupling, mindfulness meditation
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Device
Also called taVNS, Auricular Vagus Nerve Stimulation
Participants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm.
Sham StimulationDevice
Participants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group.
Mindfulness TrainingBehavioural
Also called Mindfulness Meditation, Guided Mindfulness Practice
Participants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| taVNS + Mindfulness Training | Experimental | Participants in this group will receive 30-minute daily sessions of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standardized mindfulness training for 10 consecutive days. taVNS is delivered using a wearable device targeting the cymba conchae area of the ear. Stimulation parameters include a frequency of 25 Hz and a pulse width of 200 µs. Mindfulness training involves guided audio practice focused on breath awareness and body scanning. Receives: Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS); Behavioral: Mindfulness Training |
| Sham Stimulation + Mindfulness Training | Sham comparator | Participants in this group will receive 30-minute daily sessions of sham stimulation (identical device without active current) combined with the same mindfulness training protocol as the experimental group, administered for 10 consecutive days. The sham stimulation mimics the appearance and procedure of active taVNS but delivers no electrical stimulation. Receives: Device: Sham Stimulation; Behavioral: Mindfulness Training |
What is being measured
The primary outcome is the main question the study is designed to answer.
Emotional Inhibitory Control Performance in Emotional Go/NoGo Task
Emotional inhibitory control performance will be assessed based on participants' accuracy in the emotional Go/NoGo task (i.e., proportion of correctly inhibited responses on NoGo trials). The task uses emotionally valenced facial stimuli and requires participants to withhold responses under emotional interference. Accuracy reflects participants' inhibitory control under affective load, which is the primary behavioral index of intervention efficacy.
Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)
Secondary outcomes (4)
Drift Rate Estimated by Hierarchical Drift Diffusion Model (HDDM)
Drift rate, a latent parameter derived from the HDDM, reflects the efficiency of cognitive processing and evidence accumulation during the Go/NoGo task. Higher drift rate indicates more efficient response selection under emotional conflict. HDDM modeling is conducted using trial-level reaction time and accuracy data.
Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)
Brain-Heart Coupling Strength (HRV-EEG Coupling)
Degree of brain-heart coupling is measured by calculating multiscale mutual information and maximal information coefficient (MIC) between heart rate variability (HRV) and EEG oscillations (particularly in the alpha, beta, and theta bands) during resting-state data collection. Higher coupling indicates stronger brain-autonomic integration.
Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)
Self-Reported Emotion Regulation Ability (DERS Score)
Participants complete the Difficulties in Emotion Regulation Scale (DERS), which provides a total score and subscale scores reflecting emotional awareness, impulse control, and clarity. Lower scores reflect better emotion regulation capacity.
Measured: Assessed at baseline (Day 0) and post-intervention (Day 11)
Alcohol Craving (Visual Analog Scale)
Alcohol craving is measured using a visual analog scale (VAS, 0-100), with higher scores indicating stronger desire to consume alcohol. This outcome reflects emotional-behavioral change after intervention.
Measured: Assessed at Day 0, Day 3, Day 6, Day 11
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2025
- Study start15 Mar 2024
- Primary completion31 Aug 2024
- Study completion31 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use Disorder (AUD)Studies of the same condition, open and under way.
- More trials run by Shanghai Mental Health CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shanghai Mental Health Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jiang Du, M.D, Study chair, Shanghai Mental Health Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07036055
- Sponsor's protocol ID
- JDu-015
- Status last verified
- Jun 2025
- First submitted
- 16 Jun 2025
- Last updated
- 25 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data (IPD) that underlie the published results, including behavioral performance, physiological signals (EEG/ECG), and questionnaire scores, will be shared in de-identified form. Data dictionaries will also be provided.
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Targeting Brain-Heart Coupling to Improve Emotional Inhibitory Control in Alcohol Use Disorder: Mechanistic Insights and Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Mindfulness Training
- ClinicalTrials.gov ID
- NCT07036055
- Acronym / sponsor ID
- JDu-015
- Conditions
- Alcohol Use Disorder (AUD)
- Keywords
- Alcohol Use Disorder (AUD), transcutaneous auricular vagus nerve stimulation (taVNS), brain-heart coupling, mindfulness meditation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Shanghai Mental Health CenterUniversity, hospital or other
- Study start
- 15 Mar 2024 (actual)
- Primary completion
- 31 Aug 2024 (actual)
- Study completion
- 31 Aug 2024 (actual)
- First posted
- 25 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to understand whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with mindfulness training can improve emotional inhibitory control in adults with Alcohol Use Disorder (AUD). The study also aims to explore the brain-heart coupling mechanisms underlying these control deficits.
The main questions it aims to answer are:
Do individuals with AUD have abnormal brain-heart coupling associated with impaired emotional inhibitory control? Can taVNS combined with mindfulness training enhance emotional inhibitory control in individuals with AUD compared to sham stimulation? Researchers will compare a group receiving taVNS plus mindfulness training to a group receiving sham stimulation plus mindfulness training to see whether the active intervention improves behavioral performance and brain-heart coupling.
Participants will:
Complete an emotional Go/NoGo task while EEG and ECG data are recorded Receive 10 days of either real or sham taVNS combined with mindfulness training Complete questionnaires and cognitive assessments before and after the intervention
Detailed description
This two-part clinical study investigates the mechanisms and intervention effects related to emotional inhibitory control deficits in individuals with Alcohol Use Disorder (AUD), with a specific focus on brain-heart coupling (also referred to as brain-heart interplay, BHI). The study aims to identify the neurophysiological characteristics underlying inhibitory control impairments in AUD and evaluate whether non-invasive vagus nerve stimulation combined with mindfulness training can enhance emotional regulation and cognitive function.
Study 1: Mechanism Exploration Study 1 adopts a case-control observational design. A total of 28 individuals diagnosed with AUD (based on DSM-5 criteria) and 28 age- and education-matched healthy controls are recruited. Participants complete an emotional Go/NoGo task under EEG-ECG hyperscanning. Emotional inhibitory control performance is assessed through behavioral indices (reaction time, error rate) and further analyzed using the Hierarchical Drift Diffusion Model (HDDM) to quantify latent cognitive processing parameters (e.g., drift rate, boundary separation, non-decision time). Brain-heart coupling is evaluated through resting-state EEG-ECG data using multiscale coupling coefficients and maximal information coefficient (MIC) between heart rate variability (HRV) and cortical oscillations (particularly α, β, and θ bands).
Primary outcomes include:
Drift rate and inhibitory control accuracy under emotional interference Degree of BHI (HRV-EEG coupling strength and directionality) The moderating effect of self-reported emotion regulation ability (measured via DERS)
Study 2: Intervention Evaluation
Study 2 is a single-blind randomized controlled trial (RCT) involving 60 AUD participants randomly assigned to:
Active group (n=30): taVNS combined with mindfulness training Control group (n=30): sham stimulation combined with mindfulness training Participants in both groups receive daily 30-minute sessions for 10 consecutive days. taVNS is delivered using a wearable ear-clip device targeting the auricular branch of the vagus nerve (cymba conchae), with stimulation parameters set at 25 Hz, pulse width of 200 μs, and intensity adjusted to individual sensory threshold. Mindfulness training is conducted by a trained therapist, focusing on breath awareness and body scanning.
Outcome measures are collected pre- and post-intervention and include:
Emotional inhibitory control performance under the Go/NoGo paradigm HDDM-derived cognitive parameters (e.g., drift rate) EEG-ECG-based BHI metrics (HRV-EEG coupling during rest) Self-reported anxiety (GAD-7), depressive symptoms (PHQ-9), and alcohol craving Adverse events monitoring and adherence logs Data Acquisition and Processing EEG signals are recorded using a 64-channel portable system (10-20 system); ECG is simultaneously recorded.
Signals are preprocessed in EEGLAB (bandpass filtering, artifact correction via ASR), with HRV features extracted via Kubios.
HDDM modeling is conducted in Python (Bayesian MCMC estimation), and BHI is analyzed through mutual information, MIC, and transfer entropy metrics.
Sample Size and Statistical Plan Sample size was estimated based on prior effect sizes observed in similar taVNS and mindfulness interventions. Power analysis indicated 28 subjects per group achieves >80% power to detect moderate group × time interaction effects.
Statistical analyses include:
Mixed-effects ANOVA for behavioral and neural outcomes Regression models to assess mediation and moderation effects (e.g., emotion regulation ability) Pearson/Spearman correlation between physiological and behavioral measures All analyses follow intention-to-treat principles with imputation for missing data where appropriate (e.g., multiple imputation for <10% missing).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| taVNS + Mindfulness Training | Experimental | Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Behavioral: Mindfulness TrainingParticipants in this group will receive 30-minute daily sessions of transcutaneous auricular vagus nerve stimulation (taVNS) combined with standardized mindfulness training for 10 consecutive days. taVNS is delivered using a wearable device targeting the cymba conchae area of the ear. Stimulation parameters include a frequency of 25 Hz and a pulse width of 200 µs. Mindfulness training involves guided audio practice focused on breath awareness and body scanning. |
| Sham Stimulation + Mindfulness Training | Sham comparator | Device: Sham Stimulation, Behavioral: Mindfulness TrainingParticipants in this group will receive 30-minute daily sessions of sham stimulation (identical device without active current) combined with the same mindfulness training protocol as the experimental group, administered for 10 consecutive days. The sham stimulation mimics the appearance and procedure of active taVNS but delivers no electrical stimulation. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (AUD).
- Aged 18-55 years.
- Currently in the post-acute withdrawal phase (≥2 weeks since last alcohol use).
- No severe psychiatric comorbidities (e.g., schizophrenia, bipolar disorder).
- No neurological disorders (e.g., epilepsy, traumatic brain injury).
Key exclusion criteria (5 listed)
- Dependence on other substances (except nicotine).
- Severe physical illness requiring immediate treatment.
- Active infectious diseases (e.g., HIV, hepatitis).
- Inability to complete study procedures (e.g., cognitive impairment).
- (For healthy controls in Study 1, inclusion required AUDIT score ≤8, no psychiatric/neurological history, and matched demographics.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Also: taVNS, Auricular Vagus Nerve StimulationParticipants receive transcutaneous auricular vagus nerve stimulation (taVNS) via a non-invasive ear-clip device targeting the cymba conchae. The device delivers electrical pulses at 25 Hz frequency with a pulse width of 200 µs, for 30 minutes daily over 10 consecutive days. The stimulation intensity is individually adjusted to the participant's perceptual threshold. taVNS is paired with standardized mindfulness training in this arm. | Device | taVNS + Mindfulness Training |
| Sham StimulationParticipants in this group use the same device as in the active taVNS condition, but the stimulation is deactivated. The ear-clip device is placed identically on the cymba conchae, with no electrical current delivered. This sham procedure mimics the look and feel of taVNS but serves as a placebo control. Sham stimulation is combined with the same mindfulness training as the experimental group. | Device | Sham Stimulation + Mindfulness Training |
| Mindfulness TrainingAlso: Mindfulness Meditation, Guided Mindfulness PracticeParticipants receive instructor-led mindfulness training conducted by a trained therapist. Each session lasts 30 minutes and focuses on breath awareness, body scanning, and non-judgmental awareness of internal experience. All participants (both taVNS and sham groups) receive this training daily for 10 consecutive days. | Behavioural | Sham Stimulation + Mindfulness Training, taVNS + Mindfulness Training |
Primary outcome
Emotional Inhibitory Control Performance in Emotional Go/NoGo Task
Time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)
Emotional inhibitory control performance will be assessed based on participants' accuracy in the emotional Go/NoGo task (i.e., proportion of correctly inhibited responses on NoGo trials). The task uses emotionally valenced facial stimuli and requires participants to withhold responses under emotional interference. Accuracy reflects participants' inhibitory control under affective load, which is the primary behavioral index of intervention efficacy.
4 secondary outcomes
Drift Rate Estimated by Hierarchical Drift Diffusion Model (HDDM)
Time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)
Brain-Heart Coupling Strength (HRV-EEG Coupling)
Time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)
Self-Reported Emotion Regulation Ability (DERS Score)
Time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)
Alcohol Craving (Visual Analog Scale)
Time frame: Assessed at Day 0, Day 3, Day 6, Day 11
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2025.
- Individual participant dataSharing planned: Yes. Individual participant data (IPD) that underlie the published results, including behavioral performance, physiological signals (EEG/ECG), and questionnaire scores, will be shared in de-identified form. Data dictionaries will also be provided.
Related trials for Alcohol Use Disorder (AUD)
Not yet recruitingObservational study
Disease Intervention Specialist (DIS) for SUD
Substance Use Disorder (SUD), Opioid Use Disorder
Not yet recruiting
Deaf CBT-TS to Reduce Suicide Risk
Depression - Major Depressive Disorder, Anxiety
RecruitingPhase 1
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
Not yet recruiting
eTSF for Latinx Young Adults With Alcohol Use Disorder
Alcohol Use Disorder (AUD)
Not yet recruitingObservational study
Process-Based Psychological Processes in Alcohol Use Disorder: A Case-Control Study Using PBAT, PHQ-9, and GAD-7
Alcohol Use Disorder (AUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jiang Du, M.D study chair
Shanghai Mental Health Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) and Mindfulness Training in people with Alcohol Use Disorder (AUD), run by Shanghai Mental Health Center at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Emotional Inhibitory Control Performance in Emotional Go/NoGo Task (time frame: Assessed at baseline (Day 0) and post-intervention (Day 11)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.